Sanctions regimes, export controls, and service prohibitions are evolving at speed - often faster than corporate governance frameworks can adapt. For Swiss and international businesses operating across holding structures, trading platforms, and complex supply chains, exposure can arise unexpectedly through subsidiaries, counterparties, or indirect ownership links. What appears compliant today can become a reputational and regulatory risk overnight.
This session brings together audit, legal, and compliance leaders to explore how organisations are identifying hidden sanctions exposure, strengthening onboarding and counterparty due diligence, and redesigning controls to address sudden regulatory shifts. With a practical, Swiss-focused lens, the discussion will examine how boards and compliance teams can move beyond traditional fraud controls to manage dynamic enforcement risk in an increasingly unpredictable environment.
Marco Stolla
Juan Antonio De Lassaletta Fernández
Juancho de Lassaletta joined Vifor Fresenius Medical Care Renal Pharma (VFMCRP) in August 2019 as Vice-President & Global Head Legal and Compliance.
Juancho studied law at the University of Barcelona and completed postgraduate studies at IESE Business School, Corporate Development Program (PDD).
He started his career at international law firms working during 14 years as a corporate and M&A lawyer in the life sciences spaces in the Iberian and Latin America markets.
His in-house career, as Associate to General Counsel and Head of Compliance, led him in 2015 to InsudPharma Group (generics) where he led the design and implementation of Insudpharm Global Compliance Program with special focus in Latin America.
At VFMCRP, Juancho is globally responsible for all legal, IP, litigation and compliance matters. Interface to global Fresenius Medical Care legal, IP and compliance teams, member of FMC Legal Leadership Team.
His areas of specialization are most notably BD & License-in deals with US biotechs, M&A and Compliance. He works closely with a diverse range of senior stakeholders at Vifor Pharma’s and FMC’s global headquarters, building effective relationships and driving consensus.